

# Transient I $\kappa$ B Kinase Activity Mediates Temporal NF- $\kappa$ B Dynamics in Response to a Wide Range of Tumor Necrosis Factor- $\alpha$ Doses<sup>\*[5]</sup>

Received for publication, September 14, 2005, and in revised form, November 21, 2005. Published, JBC Papers in Press, December 1, 2005, DOI 10.1074/jbc.M510085200

Raymond Cheong<sup>#1</sup>, Adriel Bergmann<sup>‡</sup>, Shannon L. Werner<sup>§</sup>, Joshua Regal<sup>§</sup>, Alexander Hoffmann<sup>§</sup>, and Andre Levchenko<sup>#2</sup>

From the <sup>#</sup>Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21218 and the <sup>§</sup>Signaling Systems Laboratory, Department of Chemistry and Biochemistry, University of California, San Diego, San Diego, California 92093

**Dynamic properties of signaling pathways control their behavior and function. We undertook an iterative computational and experimental investigation of the dynamic properties of tumor necrosis factor (TNF) $\alpha$ -mediated activation of the transcription factor NF- $\kappa$ B. Surprisingly, we found that the temporal profile of the NF- $\kappa$ B activity is invariant to the TNF $\alpha$  dose. We reverse engineered a computational model of the signaling pathway to identify mechanisms that impart this important response characteristic, thus predicting that the IKK activity profile must transiently peak at all TNF $\alpha$  doses to generate the observed NF- $\kappa$ B dynamics. Experimental confirmation of this prediction emphasizes the importance of mechanisms that rapidly down-regulate IKK following TNF $\alpha$  activation. A refined computational model further revealed signaling characteristics that ensure robust TNF $\alpha$ -mediated cell-cell communication over considerable distances, allowing for fidelity of cellular inflammatory responses in infected tissue.**

The transcription factor NF- $\kappa$ B<sup>3</sup> is a key mediator of physiologic processes such as inflammation and adaptive immunity and has been implicated in numerous pathologic states such as cancer, rheumatoid arthritis, and sepsis (1). Consequently, understanding the mechanisms of NF- $\kappa$ B activation and regulation is of prime importance. One major activator of NF- $\kappa$ B is the potent inflammatory cytokine TNF $\alpha$ . TNF $\alpha$  binds to and trimerizes its receptor, TNFR1, which leads to a receptor-associated signalosome that activates the kinase IKK (2). IKK phosphorylates I $\kappa$ B proteins, which normally sequester NF- $\kappa$ B in the cytoplasm; phosphorylated I $\kappa$ Bs are rapidly polyubiquitinated and proteasomally degraded, releasing free NF- $\kappa$ B, which translocates to the nucleus and modulates gene expression (2).

Detailed biochemical and genetic analyses over the past 25 years have helped elucidate the components that connect TNF $\alpha$  to NF- $\kappa$ B. However, relatively little is known about how these molecular players act together as a signaling system, whose complex dynamics control the time-variable activity of NF- $\kappa$ B and subsequent gene expression (3–6).

Recently, it has become apparent that analysis of the systems properties of complex biochemical pathways can benefit from an integrated approach combining systematic experimental perturbations with an associated computational analysis of molecular interactions (5, 7, 8, 10–13). This type of analysis applied to TNF $\alpha$ -induced NF- $\kappa$ B activity demonstrated that the  $\alpha$ ,  $\beta$ , and  $\epsilon$  isoforms of I $\kappa$ B cooperate to produce a biphasic NF- $\kappa$ B response (5). Varying the duration of the TNF $\alpha$  stimulus had no effect on the duration of the initial response, thus ensuring expression of some NF- $\kappa$ B-regulated genes even in response to very short stimuli (5). This analysis, however, did not address the question of how other types of signaling inputs are processed.

In this study, we analyze in detail a different type of inputs, constant stimulations at different TNF $\alpha$  doses, and experimentally and computationally analyze the resulting pathway characteristics. Surprisingly, we found that both the duration and dose of TNF $\alpha$  stimulus have little effect on the duration of the initial NF- $\kappa$ B response and that NF- $\kappa$ B responds sensitively to an extremely wide range of TNF $\alpha$  concentrations. Analysis of a computational model of the pathway predicts that these signal transduction properties are crucially dependent on the transient nature of IKK activity. The experimental confirmation of this prediction underscores the importance of the mechanisms rapidly down-regulating IKK following its activation. Based on further model analysis, we suggest that the observed dynamic properties of IKK activity are well suited to offset limitations imposed by ligand diffusion, thereby ensuring robust TNF $\alpha$ -induced NF- $\kappa$ B activity in cells of infected tissues.

## MATERIALS AND METHODS

**Cell Lines and Tissue Culture**—Immortalized 3T3 mouse embryonic fibroblasts (MEFs) were grown in Dulbecco's modified Eagle's medium with 10% bovine calf serum. Confluent, serum-starved (0.5% serum) cells were stimulated with murine TNF $\alpha$  (Roche Applied Science). In the experiments shown in Fig. 3B, cells were pretreated with 10  $\mu$ g/ml cycloheximide (Sigma Chemicals) for 30 min prior to TNF $\alpha$  stimulation.

**Electrophoretic Mobility Shift Assay**—After TNF $\alpha$  stimulation, cells were washed with ice-cold phosphate-buffered saline + 1 mM EDTA, and were scraped and collected into a microcentrifuge tube and pelleted at 2000  $\times$  g. Cells ( $\sim 10^6$ ) were resuspended in 100  $\mu$ l of CE buffer (10 mM HEPES-KOH (pH 7.9), 60 mM KCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) and vortexed for lysis. Nuclei were pelleted at 4000  $\times$  g, resuspended in 30  $\mu$ l of NE Buffer (250 mM Tris (pH 7.8), 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride), and lysed by three freeze-thaw cycles. Nuclear lysates were cleared by 14,000  $\times$  g centrifugation and the Bradford assay was used to determine protein concen-

\* This work was supported in part by Grant GM072024-01 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[5] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental information.

<sup>1</sup> Supported by the Medical Scientist Training Program at Johns Hopkins University.

<sup>2</sup> Supported by Grant GM69013-01/B270JA from the National Institutes of Health. To whom correspondence should be addressed: Dept. of Biomedical Engineering, Johns Hopkins University, 208C Clark Hall, 3400 N. Charles St., Baltimore, MD 21218. Tel.: 410-516-5584; Fax: 410-516-6240; E-mail: [alev@jhu.edu](mailto:alev@jhu.edu).

<sup>3</sup> The abbreviations used are: NF- $\kappa$ B, nuclear factor- $\kappa$ B; I $\kappa$ B, Inhibitor of NF- $\kappa$ B; IKK, I $\kappa$ B kinase; TNF $\alpha$ , tumor necrosis factor  $\alpha$ ; MEF, murine embryonic fibroblast.

## TNF $\alpha$ Dose Response Mediated by IKK

trations, which rarely varied by more than 30% from sample to sample. Protein concentrations were normalized by diluting the more concentrated samples in NE buffer. 2.5  $\mu$ l of these samples was reacted at room temperature for 15 min with 0.01 pmol of  $^{32}$ P-labeled 38-bp double-stranded oligonucleotide containing two consensus  $\kappa$ B sites (GCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGG) in binding buffer (10 mM Tris-Cl (pH 7.5), 50 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1 mM EDTA, 0.1  $\mu$ g/ $\mu$ l poly(dIdC)), for a total reaction volume of 6  $\mu$ l. Complexes were resolved on a nondenaturing 5% acrylamide (30:0.8) gel containing 5% glycerol and 1 $\times$  TGE (24.8 mM Tris, 190 mM glycine, 1 mM EDTA) and were visualized using a PhosphorImager (Molecular Dynamics). The gel images were quantitated by drawing and integrating, for each lane, equally sized boxes around the NF- $\kappa$ B-specific DNA-protein complex, around the background above it, and around the unbound probe. The unbound probe was at >20-fold excess and was used as a loading control by taking the value of the signal minus the background then dividing by the unbound probe value. The resulting specific electrophoretic mobility shift assay signal was multiplied by 1000 or some constant to provide convenient arbitrary units.

**IKK Kinase Assay**—After TNF $\alpha$  stimulation, cytoplasmic extracts were isolated from cells as described above using 200  $\mu$ l of IKK CE buffer (10 mM HEPES-KOH (pH 7.9), 250 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 0.2% Tween 20, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 mM  $\beta$ -glycerophosphate, 10 mM NaF, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>) and were normalized via Bradford assay. Cytoplasmic extracts (100  $\mu$ l) were incubated with 1  $\mu$ g of IKK $\gamma$  monoclonal antibody (BD Pharmingen) for 2 h at 4  $^{\circ}$ C and then with protein G-agarose-conjugated beads (Amersham Biosciences) for 1 h at 4  $^{\circ}$ C. After washing with IKK CE Buffer twice and kinase buffer (20 mM HEPES (pH 7.7), 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 mM  $\beta$ -glycerophosphate, 10 mM NaF, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>) once, the beads were incubated with 20  $\mu$ l of kinase buffer containing 20  $\mu$ M adenosine 5'-ATP, 10  $\mu$ Ci of [ $^{32}$ P]ATP, and 0.5  $\mu$ g of bacterially expressed GST-I $\kappa$ B $\alpha$  (1–54) substrate at 30  $^{\circ}$ C for 30 min. The reaction was resolved by 10% SDS-PAGE and was visualized and quantitated by PhosphorImager. To normalize kinase activities, a portion of the SDS gel (175–50 kDa) was transferred to polyvinylidene difluoride (Amersham Biosciences) and probed for IKK $\alpha$  (Santa Cruz Biotechnologies) using standard immunoblotting techniques.

**Canonical NF- $\kappa$ B Pathway Model**—The basic model (ordinary differential equations, pre-equilibration initial conditions, and parameter values) has been published previously (5). The model was implemented in Cellerator 1.033 (14) and analyzed with Mathematica 4.2 and 5.0 (Wolfram Research). Some parameter values were modified according to Lipniacki *et al.* (15) (see section 1.3 of the supplemental information). For input reconstruction, we assumed an activation rate of the form shown in Equation 1 and a constant inactivation rate. We also assumed that changes in TNF $\alpha$  concentration uniformly and directly affect the activation rate function. The parameter space was exhaustively sampled within biochemically plausible ranges ( $10^{-3} \leq k_{\text{init}} \leq 10^{-1}$   $\mu$ M/min,  $10^{0.25} \leq k_{\text{init}}/k_{\text{final}} \leq 10^2$ ,  $5 \leq \tau \leq 30$  min,  $10^{-2} \leq k_{\text{inact}} \leq 10^1$  min $^{-1}$ ), and results were filtered for resemblance to Fig. 1B, resulting in a unique set of parameters among those tested. See section 2 of the supplemental information for details.

**TNF $\alpha$  Diffusion Simulation**—Denoting  $C = [\text{TNF}\alpha]$ , then the spatiotemporal distribution  $C(t,r)$  of TNF $\alpha$ , considering only the processes of diffusion and first-order degradation, is determined by the mass transfer equation  $\partial C/\partial t = D\nabla^2 C - kC$ . We assumed the diffusion constant  $D = 2 \times 10^{-7}$  cm $^2$ /s, in line with estimates for diffusible factors of similar size (16, 17). The parameter  $k = 0.0275$  min $^{-1}$ , corresponding to




FIGURE 1. **NF- $\kappa$ B is sensitive to a wide range of TNF $\alpha$  concentrations.** *A*, dose response of cells to TNF $\alpha$ . Data shown are electrophoretic mobility shift assays of nuclear NF- $\kappa$ B from MEFs stimulated continuously with TNF $\alpha$  for the indicated time and dose. Results are representative of four other replicates. *B*, quantification of *A*, where 10, 1, 0.1, and 0.01 ng/ml TNF $\alpha$  are shown in light red, red, green, and blue, respectively.

a half-life of 25 min, and represents loss of TNF $\alpha$  because of degradation and adherence to extracellular matrix proteins. TNF $\alpha$  secretion was modeled as a spherically symmetric flux of TNF $\alpha$  from a sphere of radius 10  $\mu$ m, with the flux magnitude set so that the concentration at the source surface was  $\sim$ 10 ng/ml. With respect to time, TNF $\alpha$  secretion was modeled as a rectangular pulse of a 10-min duration. Finally, we imposed the boundary condition that  $C \rightarrow 0$  as  $r \rightarrow \infty$ . The simulation was performed in Femlab 3.1 (Comsol, Burlington, MA). Simulations were run for different values of  $D$ ,  $k$ , pulse length, and flux magnitude, which did not qualitatively affect any of the conclusions reported in the body of the paper. See section 3 of the supplemental information for extrapolation of the IKK response to arbitrary TNF $\alpha$  time courses.

## RESULTS

**NF- $\kappa$ B Is Sensitive to a Wide Range of TNF $\alpha$  Concentrations**—To investigate the response of NF- $\kappa$ B to different TNF $\alpha$  doses, we exposed MEFs to TNF $\alpha$  over a concentration range spanning three orders of magnitude (0.01–10 ng/ml). NF- $\kappa$ B in these experiments was found to respond robustly and sensitively throughout this range, including the lowest dose of TNF $\alpha$ , as measured by electrophoretic mobility shift assay (Fig. 1A). This experiment, in which the duration of TNF $\alpha$  stimulation is held fixed (chronic) while altering the amplitude, complements our previous work in which the amplitude of TNF $\alpha$  was held fixed (10 ng/ml) while the duration was altered (5). Remarkably, in both cases, cells show a stereotypical response of an initial peak of NF- $\kappa$ B activity lasting 60–75 min (Fig. 1B). These results show that the NF- $\kappa$ B pathway is sensitive to a wide range of TNF $\alpha$  concentrations, which may help ensure a response to local TNF $\alpha$  signals in innate immune responses (see below).

**Transient IKK Activity Generates Observed Dynamics in the Computational Model**—To investigate the molecular basis underlying the robust dynamics of NF- $\kappa$ B activation, we attempted to recapitulate the dose response in our computational model of the NF- $\kappa$ B pathway. The model included detailed interactions between IKK, I $\kappa$ B, and NF- $\kappa$ B, and reflecting contemporary uncertainty about the mechanisms of IKK regulation (18), assumed an exponential decay curve for IKK during chronic TNF $\alpha$  stimulation. The model was previously validated for TNF $\alpha$  doses of 10 ng/ml, so to simulate lower TNF $\alpha$  concentrations we decreased the initial level of IKK. However, our simulation results did not adequately fit the measured responses as even a 10-fold reduction in IKK greatly delayed the onset of predicted NF- $\kappa$ B activity (Fig. 2A), suggesting that the model requires modification to recapitulate the experiment.

As a control, we first addressed whether the discrepancy between model prediction and experiment is because of a simple misestimation of rate constants described by the parameters in the model. Out of




FIGURE 2. **Input constructed from the observed output rectifies the model.** A, model predictions do not agree with observed dynamics. The original model from Ref. 5 was run with initial IKK set to 0.10 (red), 0.02 (green), and 0.01 (blue)  $\mu\text{M}$  to simulate the effect of different TNF $\alpha$  doses. The predicted dynamics differ from the observed dynamics in Fig. 1. B, generalized model input scheme. A generator of IKK profiles was created (gray box) using arbitrary functions  $f_{act}(t)$  and  $f_{inact}(t)$  to represent the IKK activation and inactivation rates, respectively. The symbol " $\emptyset$ " represents a source or sink for active IKK. The output of this profile generator feeds into the core model, influencing the behavior of the I $\kappa$ B-NF- $\kappa$ B negative feedback loop (yellow box). C, distribution of fits under a linear model of IKK regulation. The rate functions from B are assumed to be constant, and for each pair of rates tested the corresponding square is colored if the initial peak in NF- $\kappa$ B activity is high and timely (dark gray) or if the trough in NF- $\kappa$ B activity is low and timely (light gray). The regions do not overlap, showing that no pair of constant rates gives a complete fit to experiment and suggesting that a time-varying rate is needed (arrow). D, activation rate functions identified by exhaustive screening. Activation rates corresponding to high (red), medium (green), and low (blue) levels of TNF $\alpha$  are shown. E, the IKK and F, NF- $\kappa$ B activity time-courses predicted by the model using the functions in D and an inactivation rate of  $k_{inact} = 0.1 \text{ min}^{-1}$ . Colors correspond to D.

10,000 parameter sets generated by random sampling within  $\pm 2$  orders of the nominal values, none fit the dose response while maintaining previously validated properties of the model (5). Sampling parameters in a way biased toward producing a fit, such as with evolutionary algorithms (19), also generated no fits. The results obtained by these naïve sampling methods were then confirmed by rational analysis of the model. Systematic dissection of how parameters influence key conserved features of the NF- $\kappa$ B temporal profile (peak timing and amplitude) revealed two independent effects, neither of which could be employed to reconcile the model and experiment without sacrificing previously validated properties of the model (see supplemental information, section 1). This rules out simple misestimation in parameter values as the source of discrepancy and suggests that the model should be extended to more fully describe the signaling pathway (20).

Because the model has successfully recapitulated several dynamic properties of the pathway (5), we surmised that the core model is essentially correct but that interactions with external components should be re-evaluated. One such component is the dynamic profile of IKK activity in response to TNF $\alpha$  stimulation, which serves as the input for the core model of the I $\kappa$ B-NF- $\kappa$ B signaling module (Fig. 2B). Thus we used the computational model to identify the temporal profiles of IKK activity that produce the observed NF- $\kappa$ B dynamics, essentially reverse engineering the input from the known output.

To screen for IKK profiles that could produce the NF- $\kappa$ B response, we created a generator of IKK temporal profiles and linked the generator to the model. This is shown schematically in Fig. 2B. Active IKK is generated through new protein synthesis or by activation from an inac-


tive state according to some time-varying activation rate, then removed by protein degradation or inactivation according to some time-varying inactivation rate (Fig. 2B, gray box). One or both of these steps may be dependent on TNF receptor activation by TNF $\alpha$ . Additionally, IKK provides input into the core model (Fig. 2B, yellow box) by interacting with I $\kappa$ B, whose negative feedback to NF- $\kappa$ B is the central feature of the core model.

With the IKK profile generator written in this general form, our task is to identify activation and inactivation rate functions that produce the observed NF- $\kappa$ B dynamics. When both functions are temporally constant, no pair of rates can reproduce the response to high TNF $\alpha$  (Fig. 2C), suggesting that the regulation of IKK activity is nonlinear. To understand the nature of this nonlinearity, we examined the distribution of constant rates for which either the peak (Fig. 2C, dark gray) or the trough fit (Fig. 2C, light gray). Because all TNF $\alpha$  doses produce NF- $\kappa$ B temporal profiles that contain a peak between 15 and 45 min followed by a trough between 60 and 90 min (Fig. 1B), we concluded that the IKK activation rate may begin in the regime where the peak fits then decrease in time to the regime where the trough fits (as if to follow the arrow in Fig. 2C).

To test this possibility, we assumed a simple functional form (Equation 1) for an activation rate that decreases exponentially from a high initial value ( $k_{init}$ ) to low final value ( $k_{final}$ ) in about time  $\tau$ , while holding the inactivation rate ( $k_{inact}$ ) constant as seen here.

$$f_{act}(t) = (k_{init} - k_{final})(k_{init}/k_{final})^{-t/\tau} + k_{final} \quad (\text{Eq. 1})$$





**FIGURE 3. Experiment validates prediction of transient IKK activity.** *A*, dose response of IKK activity. MEFs were stimulated with TNF $\alpha$  for the indicated time and dose, and kinase activity of immunoprecipitated IKK complex was measured against a GST-I $\kappa$ B $\alpha$  substrate. The *bottom panel* shows an example control for IKK complex immunoprecipitation efficiency. Timing of transient IKK activity matches the prediction in Fig. 2. *B*, IKK activity profile in MEFs following stimulation with 1 ng/ml TNF $\alpha$  for the indicated times in the presence or absence of 10  $\mu$ g/ml cycloheximide. Immunoprecipitation controls are shown.

This functional form, combined with a simple method for representing different TNF $\alpha$  concentrations (see “Materials and Methods”), allowed us to fully specify the IKK profile in response to a range of TNF $\alpha$  with only four parameters. An exhaustive grid-based search of the parameter space (see supplemental information, section 2) uncovered exactly one parameter set out of 5615 tested that reproduces the response to different TNF $\alpha$  concentrations while maintaining previously validated properties of the model, suggesting that the observed output can only be produced by a very specific IKK activity profile. The activation rate functions thus identified (Fig. 2*D*) produce transient IKK activity at all TNF $\alpha$  doses (Fig. 2*E*) and result in NF- $\kappa$ B profiles (Fig. 2*F*) whose initial duration is fixed but whose amplitude varies with TNF $\alpha$  concentration, as desired. Thus, the model strongly suggests that the IKK activity profile has to be transient at all TNF $\alpha$  doses.


*Predicted Transient IKK Activity Profile Is Verified Experimentally*—The model-based reconstruction of IKK activity gives rise to an experimentally testable prediction: in response to a wide range of TNF $\alpha$  concentrations, IKK activity should peak at around 10 min and decrease over the next 20 min to a low level above basal activity (Fig. 2*E*). To further gauge the strength of this prediction, we chose other activation and inactivation rate functions to systematically test similarly shaped IKK profiles but with different peak timings and peak widths. The results showed that the specific profiles in Fig. 2*E* gave a near optimal fit with the experimentally measured NF- $\kappa$ B time courses (data not shown). Therefore, the dynamics of IKK activity are highly constrained. To validate this prediction, we measured the actual IKK activity in MEFs (Fig. 3*A*), revealing a very close agreement with the model predictions, especially in terms of the timing of the activation peak. Also, consistent with the idea that the IKK profile is highly constrained, IKK profiles display similar shape and timing when measured in multiple other cell types at 10 ng/ml TNF $\alpha$  or higher (21–26), although the significance of these IKK kinetics was not previously interpreted. The unexpected insight provided by our model, validated experimentally, is that a rapid decrease in IKK activity is required to explain the dependence of the amplitude, dura-

tion, and timing of the initial peak of NF- $\kappa$ B activity in response to a wide range of TNF $\alpha$  concentrations.

Given the requirement for fast IKK down-regulation in eliciting NF- $\kappa$ B activity in response to TNF $\alpha$ , we considered the question of what biochemical mechanisms could mediate it. The computational model does not strongly constrain the mechanism, because the activation and inactivation rate functions can be coordinately changed (equivalent to different biochemical mechanisms) without changing the overall IKK activity profile, resulting in the same NF- $\kappa$ B dynamics (data not shown). Instead, we considered this question in the context of known IKK inhibitors. One possible mediator of IKK down-regulation is A20, an inhibitor of RIP (27), which is transcriptionally up-regulated by NF- $\kappa$ B within 30 min (6), thus potentially forming a negative feedback loop. We explored whether, as previously suggested (15), A20 is essential for the control of dynamics of early IKK and NF- $\kappa$ B activation. However, IKK activity is down-regulated at 30 min following onset of stimulation even with very low concentrations of TNF $\alpha$  making it unlikely that feedback via A20 is solely responsible for regulating the dynamics of the IKK activity profile. Consistent with this, in cells exposed to cycloheximide, an inhibitor of new protein synthesis, IKK activity is still high at 10 min and low at 60 min (Fig. 3*B*). Furthermore, IKK activity in A20-deficient cells still shows a peak at around 10 min, although attenuation at later times is defective (24, 28). We also considered that if A20 negative feedback was solely responsible for early down-regulation of IKK, it would be difficult to infer IKK activity profiles from the NF- $\kappa$ B activity profile, as feedbacks generally preclude one-to-one input-output mapping. Although NF- $\kappa$ B-regulated IKK inhibitors like A20 may play a late role in IKK regulation, our results suggest that early IKK inhibition is likely not mediated by NF- $\kappa$ B up-regulation of A20 or similar feedback mechanism.

*High Sensitivity of NF- $\kappa$ B to TNF $\alpha$  May Provide Robust Signaling at a Distance*—Finally, we attempted to understand the dynamic properties of the pathway in a physiologic context. The primary physiologic function of TNF $\alpha$  is to mediate innate immune responses in response to infection (29). The effects of TNF $\alpha$  are local as enforced by multiple mechanisms. TNF $\alpha$  expression by pathogen-activated macrophages is brief and self-limited, because phagocytosis of pathogens rapidly removes the inciting stimulus, and prolonged exposure to TNF $\alpha$  can both lead to quick apoptosis of TNF $\alpha$ -secreting macrophages (30) and inappropriately induce systemic responses (31, 32). Several postinduction repression and autocrine inhibition mechanisms have been described for TNF $\alpha$  expression (33), and both TNF $\alpha$  mRNA and secreted protein have a short half-life (34–36). At the same time, the affinity of TNF to its receptors is similar to its affinity to extracellular matrix proteins (37) and the molecular mass of TNF $\alpha$  is high (51 kDa as active trimer), impeding diffusion and increasing buffering through nonspecific binding. All of these mechanisms serve to limit the effects of TNF $\alpha$  to a local tissue environment.

To model the local spread of TNF $\alpha$  in an infected tissue in a way consistent with the above, we considered the simple scenario in which a TNF $\alpha$ -secreting cell (or cluster of cells) produces a transient pulse of TNF $\alpha$ , which then diffuses into the surroundings, where it is subject to degradation and buffering. The real tissue environment is intricate and probably involves the presence of additional cytokines and more complex spatiotemporal patterns of TNF $\alpha$  secretion, but these simplifying assumptions can be viewed as a limiting case designed to investigate whether weak TNF $\alpha$  signaling can still be effective. Our simulations show that in this scenario nearby cells would experience a pulse of TNF $\alpha$  whose duration and amplitude both decrease rapidly with distance (Fig. 4, *A* and *B*, supplemental movie S1). We then considered how



**FIGURE 4. NF- $\kappa\text{B}$  pathway dynamics may provide robust cell-cell signaling by TNF $\alpha$  diffusion.** *A*, simulation of diffusive spread of a pulse of TNF $\alpha$  in an infected tissue, causing nearby cells to experience pulses of TNF $\alpha$  of different amplitudes and durations. The red circle marks the TNF $\alpha$  source, and the green and blue circles mark points at which the local TNF $\alpha$  concentration is sampled at the indicated times, as shown in the upper right and lower right corners, respectively. The simulated region is a cube 1000  $\mu\text{m}$  on each edge, and each panel represents a cross-section through the center of this space. See also supplemental movie 1. *B*, the maximum signal decays approximately exponentially with distance. Curves shown are maximum (dashed) and log maximum (solid) TNF $\alpha$  signal experienced because of diffusive spread, normalized to 0.01–10 ng/ml. *C* and *D*, simulated NF- $\kappa\text{B}$  response to TNF $\alpha$  time courses resulting from diffusive spread of a TNF $\alpha$  pulse. At nominal parameters (solid black), 6 $\times$  flux (dotted blue), 0.2 $\times$  flux (dashed blue), 20 min TNF $\alpha$  pulse (dotted orange), or 5 min TNF $\alpha$  pulse (dashed orange), the NF- $\kappa\text{B}$  response amplitude decays smoothly with distance, whereas duration of signaling (thresholded at 0.1  $\mu\text{M}$ ) is always 40–60 min. *E*, effect of distance on the TNF $\alpha$ , IKK, and NF- $\kappa\text{B}$  profiles. In each panel, simulated time courses at 100 (light red), 200 (red), 300 (green), and 400 (blue)  $\mu\text{m}$  from the source are shown, time-shifted for clarity. Due in part to fast IKK inhibition, distance-related changes in the amplitude and duration of the TNF $\alpha$  experienced (light gray) affect the amplitude but not temporal profile of IKK (dark gray) and NF- $\kappa\text{B}$  (yellow) activity.

target cells might respond to such local changes in TNF $\alpha$  concentration by coupling the TNF $\alpha$  diffusion simulation (Fig. 4*A*) to the NF- $\kappa\text{B}$  pathway model (Fig. 2*B*).

At various distances from the model TNF $\alpha$  source cell (e.g. a macrophage), we determined the local kinetic TNF $\alpha$  profiles due to diffusive spread and related them to the corresponding IKK activities (supplemental information, Section 3) and the resulting outputs of the NF- $\kappa\text{B}$  pathway. The simulations reveal that the NF- $\kappa\text{B}$  response amplitude (Fig. 4*C*) depends linearly on the distance from the TNF $\alpha$  source, whereas the duration of the response remains approximately constant (Fig. 4*D*). Furthermore, this qualitative behavior does not depend on the precise concentration or duration of the TNF $\alpha$  pulse (Fig. 4, *C* and *D*), nor on precise value of diffusivity or degradation rate/buffering strength (not shown). Rather, this signaling behavior is essentially because of the exponential drop of the maximum TNF $\alpha$  concentration with distance (Fig. 4*B*) coupled with logarithmic variation of the maximum NF- $\kappa\text{B}$

activity with TNF $\alpha$  input (Fig. 1*B*), and the remarkable independence of the duration of the initial NF- $\kappa\text{B}$  response on both the duration and the amplitude of the TNF $\alpha$  stimulus.

Importantly, the duration of NF- $\kappa\text{B}$  activity remains approximately constant even at distances ( $\sim 500$   $\mu\text{m}$ ) where the activity amplitude becomes negligible (Fig. 4, *C* and *D*). In comparison, the theoretical limit for cell-cell signaling has been estimated to be a few hundred microns (16). Thus, our results suggest that one function of the dynamic properties of the IKK/NF- $\kappa\text{B}$  pathway illuminated in this study is to provide a reliable and immediate response to TNF $\alpha$  even at limiting distances in infected tissue.

## DISCUSSION

Here we undertook an iterative computational and experimental study of the dynamics of NF- $\kappa\text{B}$  in response to different TNF $\alpha$  doses. We present experimental data that show that NF- $\kappa\text{B}$  responds sensi-

tively to TNF $\alpha$  over a concentration range of three orders of magnitude. Interestingly, the duration of the initial response is constant with respect to TNF $\alpha$  dose, a dynamic property without an obvious mechanistic or teleologic explanation.

Computational modeling of NF- $\kappa$ B signaling helped suggest both the mechanistic basis and possible physiologic significance of the dynamic properties of the pathway. We found, by reconstructing the input into the I $\kappa$ B-NF- $\kappa$ B module, that one property mechanistically required for the observed NF- $\kappa$ B activity profiles is highly transient IKK activity with a peak at around 10 min following TNF $\alpha$  stimulation at different doses. Such reverse engineering may be useful in investigating other systems, but it is often difficult because of nonlinearities present in signaling systems and the large number of permissible input functions (38). We overcame these obstacles by starting with a simple linear case and using the results to guide the choice of nonlinear assumptions as well as by keeping the parameter space small to allow for exhaustive testing of all reasonable possibilities. Systematic perturbation of the revised model then indicated that the IKK activity was highly constrained by the observed output and this strong prediction was confirmed by kinase assays of IKK $\beta$  activity.

The molecular mechanism for fast inactivation of IKK remains mysterious. It is unlikely that postinduction attenuation of IKK activity is solely dependent on NF- $\kappa$ B-regulated IKK inhibitors like A20. Other IKK inhibitors like PP2C $\beta$ , PP2A, CYLD, hTid-1, and Hsp70 might be involved (25, 39–44), or regulation of the conformational state of IKK $\beta$  via hyperautophosphorylation of its C terminus could lead to IKK inactivation (22). Importantly, the disruption of the C-terminal sites in IKK $\beta$  leads to persistently active IKK upon stimulation (22), suggesting inhibitory autophosphorylation as the major source of fast IKK down-regulation. High basal activity of IKK phosphorylation mutants prohibited us from easily testing this mechanism (22) but highlights the need for additional study into the mechanisms of IKK regulation.

The computational model also suggested how the characteristic NF- $\kappa$ B pathway dynamics might facilitate innate immunity in tissues during infection. TNF $\alpha$  may be secreted by a cell or a small cluster of cells (e.g. macrophages) thereby signaling to target cells located nearby. TNF $\alpha$  is a poor signaling agent because it is secreted briefly at low levels and diffuses slowly, but our results paint an intuitively appealing picture of why the local action of TNF $\alpha$  in innate immunity, acting through activation of NF- $\kappa$ B, can be both robust and efficient. TNF $\alpha$  can effectively activate NF- $\kappa$ B for prolonged periods in cells, possibly to ensure efficient triggering of gene transcription, even at near-limiting distances. The spatially graded nature of the response amplitude (Fig. 4E) also may ensure that cells respond commensurate with their distance from the source of danger (9), which could provide an economical result in which every responsive cell is neither excessively nor inadequately stimulated. These dynamic properties, in combination with information provided by other extracellular cues, could help prime and coordinate tissue responses to local infection. As such, IKK regulatory mechanisms may represent sensitive clinical targets in diseases with aberrant innate immune system activity.

### REFERENCES

- Cheong, R., and Levchenko, A. (2005) in *Encyclopedia of Molecular Cell Biology and Medicine* (Meyers, H. A., ed) Vol. 14, pp. 437–472, John Wiley & Sons, New York
- Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) *Cell Death Differ.* **10**, 45–65
- Barken, D., Wang, C. J., Kearns, J., Cheong, R., Hoffmann, A., and Levchenko, A.

- (2005) *Science* **308**, 52a
- Hoffmann, A., Leung, T. H., and Baltimore, D. (2003) *EMBO J.* **22**, 5530–5539
- Hoffmann, A., Levchenko, A., Scott, M. L., and Baltimore, D. (2002) *Science* **298**, 1241–1245
- Zhou, A., Scoggins, S., Gaynor, R. B., and Williams, N. S. (2003) *Oncogene* **22**, 2054–2064
- Bhalla, U. S., Ram, P. T., and Iyengar, R. (2002) *Science* **297**, 1018–1023
- Ferrell, J. E., Jr., and Machleder, E. M. (1998) *Science* **280**, 895–898
- Matzinger, P. (1998) *Semin. Immunol.* **10**, 399–415
- Klein, D. E., Nappi, V. M., Reeves, G. T., Shvartsman, S. Y., and Lemmon, M. A. (2004) *Nature* **430**, 1040–1044
- Ozbudak, E. M., Thattai, M., Lim, H. N., Shraiman, B. I., and Van Oudenaarden, A. (2004) *Nature* **427**, 737–740
- Sasagawa, S., Ozaki, Y., Fujita, K., and Kuroda, S. (2005) *Nat. Cell Biol.* **7**, 365–373
- Swameye, I., Muller, T. G., Timmer, J., Sandra, O., and Klingmuller, U. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 1028–1033
- Shapiro, B. E., Levchenko, A., Meyerowitz, E. M., Wold, B. J., and Mjolsnes, E. D. (2003) *Bioinformatics* **19**, 677–678
- Lipniacki, T., Paszek, P., Brasier, A. R., Luxon, B., and Kimmel, M. (2004) *J. Theor. Biol.* **228**, 195–215
- Francis, K., and Palsson, B. O. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 12258–12262
- Goodhill, G. J. (1997) *Eur. J. Neurosci.* **9**, 1414–1421
- Ghosh, S., and Karin, M. (2002) *Cell* **109**, (suppl.) 81–96
- Banzhaf, W. (1998) *Genetic Programming: an Introduction on the Automatic Evolution of Computer Programs and Its Applications*, Morgan Kaufmann, San Francisco, CA
- von Dassow, G., Meir, E., Munro, E. M., and Odell, G. M. (2000) *Nature* **406**, 188–192
- Aupperle, K. R., Bennett, B. L., Boyle, D. L., Tak, P. P., Manning, A. M., and Firestein, G. S. (1999) *J. Immunol.* **163**, 427–433
- Delhase, M., Hayakawa, M., Chen, Y., and Karin, M. (1999) *Science* **284**, 309–313
- DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) *Nature* **388**, 548–554
- Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P., and Ma, A. (2000) *Science* **289**, 2350–2354
- Prajapati, S., Verma, U., Yamamoto, Y., Kwak, Y. T., and Gaynor, R. B. (2004) *J. Biol. Chem.* **279**, 1739–1746
- Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) *Cell* **91**, 243–252
- Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V., and Dixit, V. M. (2004) *Nature* **430**, 694–699
- Werner, S., Barken, D., and Hoffmann, A. (2005) *Science* **309**, 1857–1861
- Tracey, K. J., and Cerami, A. (1992) *Proc. Soc. Exp. Biol. Med.* **200**, 233–239
- Xaus, J., Comalada, M., Valledor, A. F., Lloberas, J., Lopez-Soriano, F., Argiles, J. M., Bogdan, C., and Celada, A. (2000) *Blood* **95**, 3823–3831
- Blander, J. M., and Medzhitov, R. (2004) *Science* **304**, 1014–1018
- Klein, R. D., Su, G. L., Schmidt, C., Aminlari, A., Steinstraesser, L., Alarcon, W. H., Zhang, H. Y., and Wang, S. C. (2000) *J. Surg. Res.* **94**, 159–166
- Baer, M., Dillner, A., Schwartz, R. C., Sedon, C., Nedospasov, S., and Johnson, P. F. (1998) *Mol. Cell. Biol.* **18**, 5678–5689
- Beutler, B. A., Milsark, I. W., and Cerami, A. (1985) *J. Immunol.* **135**, 3972–3977
- Reeves, R., and Magnuson, N. S. (1990) *Prog. Nucleic Acids Res. Mol. Biol.* **38**, 241–282
- Stoecklin, G., Lu, M., Rattenbacher, B., and Moroni, C. (2003) *Mol. Cell. Biol.* **23**, 3506–3515
- Alon, R., Cahalon, L., Hershkovitz, R., Elbaz, D., Reizis, B., Wallach, D., Akiyama, S. K., Yamada, K. M., and Lider, O. (1994) *J. Immunol.* **152**, 1304–1313
- Hartwell, L. H., Hopfield, J. J., Leibler, S., and Murray, A. W. (1999) *Nature* **402**, Suppl. 6761, 47–52
- Brummelkamp, T. R., Nijman, S. M., Dirac, A. M., and Bernards, R. (2003) *Nature* **424**, 797–801
- Cheng, H., Cenciarelli, C., Nelkin, G., Tsan, R., Fan, D., Cheng-Mayer, C., and Fidler, I. J. (2005) *Mol. Cell. Biol.* **25**, 44–59
- Fu, D. X., Kuo, Y. L., Liu, B. Y., Jeang, K. T., and Giam, C. Z. (2003) *J. Biol. Chem.* **278**, 1487–1493
- Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., and Courtois, G. (2003) *Nature* **424**, 801–805
- Ran, R., Lu, A., Zhang, L., Tang, Y., Zhu, H., Xu, H., Feng, Y., Han, C., Zhou, G., Rigby, A. C., and Sharp, F. R. (2004) *Genes Dev.* **18**, 1466–1481
- Trompouki, E., Hatzivassiliou, E., Tschirritzis, T., Farmer, H., Ashworth, A., and Moulton, G. (2003) *Nature* **424**, 793–796

**Transient I $\kappa$ B Kinase Activity Mediates Temporal NF- $\kappa$ B Dynamics in Response to a Wide Range of Tumor Necrosis Factor- $\alpha$  Doses**

Raymond Cheong, Adriel Bergmann, Shannon L. Werner, Joshua Regal, Alexander Hoffmann and Andre Levchenko

*J. Biol. Chem.* 2006, 281:2945-2950.

doi: 10.1074/jbc.M510085200 originally published online December 1, 2005

---

Access the most updated version of this article at doi: [10.1074/jbc.M510085200](https://doi.org/10.1074/jbc.M510085200)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2005/12/02/M510085200.DC1>

This article cites 43 references, 21 of which can be accessed free at <http://www.jbc.org/content/281/5/2945.full.html#ref-list-1>